Brought to you by 
NeurogesX gets $23mm in Series B round
18 Feb 2002
Executive Summary
NeurogesX (develops products to treat nerve signaling disorders) raised $22.86mm through a Series B private placement led by Walden International. Also participating in the round were Alta Partners, Arch Venture Partner, Montreux Equity Partners, Grove Street Advisors, Teachers Insurance and Annuity Association, Duke University, and the University of North Carolina.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeurogesX gets $23mm in Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice